A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.

by Patrick A Ott, Anne Hamilton, Amanda Jones, Naomi Haas, Tsiporah Shore, Sandra Liddell, Paul J Christos, L Austin Doyle, Michael Millward, Franco M Muggia, Anna C Pavlick
Published 2010-01-01

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal...

by Elizabeth K. Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch, Ursula A. Matulonis, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Joyce F. Liu
Published 2020-05-01

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

by Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Published 2019-07-01